Inhibrx INBRX-106 Phase 2 HNSCC cORR 44.0%; 3 CRs observed
Inhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), showing a 44.0% confirmed objective response rate (cORR) for the combination arm, a 22.6% absolute increase over pembrolizumab monotherapy. The study also reported three complete responses in the combination arm and robust T-cell activation, with a generally manageable safety profile. Based on these promising results, the company plans to initiate the Phase 3 portion of the HexAgon study in Q3 2026 and expand INBRX-106 evaluation into broader indications, including NSCLC. The company also provided updates on its ozekibart (INBRX-109) program, highlighting strong results in chondrosarcoma and Ewing sarcoma.
Key Highlights
- INBRX-106 combination arm achieved 44.0% confirmed objective response rate (cORR) in HNSCC.
- This represents a 22.6% absolute increase in cORR compared to 21.4% for pembrolizumab alone.
- Three complete responses were observed in the INBRX-106 combination arm, with none in the control arm.
- Pharmacodynamic data showed up to a 15-fold increase in T-cell proliferation in combination-treated patients.
- The Phase 3 portion of the HexAgon study for HNSCC is planned to begin in Q3 2026.
- A new study for INBRX-106 in perioperative non-small cell lung cancer (NSCLC) will initiate later this quarter.
- Ozekibart (INBRX-109) demonstrated a 52% reduction in progression or death risk in chondrosarcoma.
- Ozekibart (INBRX-109) achieved a 64.5% objective response rate in Ewing sarcoma from 31 evaluable patients.